title: Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review.
abstract: Peripheral neurotoxicity is a major complication associated with the use of chemotherapeutic agents such as platinum compounds, taxanes and vinca alkaloids. The neurotoxicity of chemotherapy depends not only on the anticancer agent(s) used, the cumulative dose and the delivery method, but also on the capacity of the nerve to cope with the nerve-damaging process. The sensory and motor symptoms and signs of neurotoxicity are disabling, and have a significant impact on the quality of life of cancer patients. Moreover, the risk of cumulative toxicity may limit the use of highly effective chemotherapeutic agents. Therefore, prophylaxis and treatment of peripheral neurotoxicity secondary to chemotherapy are major clinical issues. Acetyl-L-carnitine (ALC), the acetyl ester of L-carnitine, plays an essential role in intermediary metabolism. Some of the properties exhibited by ALC include neuroprotective and neurotrophic actions, antioxidant activity, positive actions on mitochondrial metabolism, and stabilisation of intracellular membranes. ALC has demonstrated efficacy and high tolerability in the treatment of neuropathies of various aetiologies, including chemotherapy-induced peripheral neuropathy (CIPN). In several experimental settings, the prophylactic administration of ALC prevented the occurrence of peripheral neurotoxicity commonly induced by chemotherapeutic agents. In animal models of CIPN, ALC administration promoted the recovery of nerve conduction velocity, restored the mechanical nociceptive threshold, and induced analgesia by up-regulating the expression of type-2 metabotropic glutamate receptors in dorsal root ganglia. These results, plus the favourable safety profile of ALC in neuropathies of other aetiologies, have led to the effects of ALC on CIPN being investigated in cancer patients. Preliminary results have confirmed the reasonably good tolerability profile and the efficacy of ALC on CIPN. The present studies support the use of ALC in cancer patients with persisting neurotoxicity induced by paclitaxel or cisplatin treatment.
authors: Divisione di Neurologia, Ospedale Civile di Rovigo, Rovigo, Italy. ddegrandis@iol.it
authors: Domenico
authors: D
authors: De Grandis
mesh_terms: D000108:Acetylcarnitine / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control
chemical_list: D000970:Antineoplastic Agents; D018697:Nootropic Agents; D000108:Acetylcarnitine
references: Clin Oncol (R Coll Radiol). 2005 Jun;17(4):271-6
references: 15997923
references: Lung Cancer. 2004 Mar;43(3):247-57
references: 15165082
references: Eur J Cancer. 2005 Aug;41(12):1746-50
references: 16039110
references: Mol Pain. 2006 Jun 09;2:20
references: 16764720
references: Tumori. 2005 Mar-Apr;91(2):135-8
references: 15948540
references: Mol Pharmacol. 2002 May;61(5):989-96
references: 11961116
references: J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91
references: 15547181
references: Clin J Oncol Nurs. 2003 May-Jun;7(3):299-303
references: 12793336
references: Cancer. 1990 Sep 15;66(6):1117-23
references: 2169332
references: J Neurooncol. 1997 Oct;35(1):47-53
references: 9266440
references: Pain. 2004 May;109(1-2):132-42
references: 15082135
references: J Clin Oncol. 1992 May;10(5):718-26
references: 1569444
references: Acta Neuropathol. 1992;84(4):364-71
references: 1441917
references: Int J Gynecol Cancer. 1995 May;5(3):161-169
references: 11578472
references: Int J Gynecol Cancer. 2003 Jul-Aug;13(4):428-34
references: 12911718
references: Clin Cancer Res. 2003 Nov 15;9(15):5756-67
references: 14654561
references: Neurology. 1998 Sep;51(3):868-70
references: 9748043
references: Cancer Chemother Pharmacol. 1989;25(1):62-4
references: 2556219
references: Neurology. 2005 Jan 11;64(1):26-31
references: 15642899
references: Minerva Anestesiol. 2006 Mar;72(3):151-69
references: 16493391
references: Drugs. 2003;63(15):1549-63
references: 12887262
references: Anticancer Res. 2005 Jul-Aug;25(4):2681-7
references: 16080512
references: Neurology. 1989 Mar;39(3):368-73
references: 2564647
references: J Natl Cancer Inst Monogr. 1993;(15):107-15
references: 7912516
references: Neurosci Lett. 2006 Apr 24;397(3):219-23
references: 16406309
references: Ann Oncol. 1998 Apr;9(4):443-7
references: 9636837
references: Semin Oncol. 2006 Feb;33(1):15-49
references: 16473643